AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6%
Fri, 15 Nov

AUROBINDO PHARMA has announced its results for the quarter ended September 2019. Here is a detailed performance review of the same:

AUROBINDO PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Sep-18*
3
Jun-19*
3
Sep-19*
QoQ ChangeYoY Change
Net SalesRs m47,51454,44656,0052.9%17.9%
Other incomeRs m26315820630.7%-21.5%
TurnoverRs m47,77754,60456,2112.9%17.7%
ExpensesRs m37,65142,98244,6033.8%18.5%
Gross profitRs m9,59411,33711,275-0.6%17.5%
DepreciationRs m1,6372,4092,4331.0%48.6%
InterestRs m354499409-17.9%15.7%
Profit before taxRs m7,8668,5878,6380.6%9.8%
TaxRs m1,7542,2782,244-1.5%27.9%
Profit after taxRs m6,1126,3106,3951.3%4.6%
Gross profit margin%20.220.820.1
Effective tax rate%22.326.526.0
Net profit margin%12.811.611.4
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 17.9% on a year-on-year (YoY) basis. The expenses were up by 18.5% YoY during the same period.
  • The company's operating profit increased by 17.5% YoY during the quarter. Consequently, operating profit margins remained same and stood at 20.1% in 2QFY20.
  • Depreciation charges increased by 48.6% and finance costs increased by 15.7% YoY, respectively.
  • Other income declined by 21.5% YoY during the quarter.
  • Net profit for the quarter increased by 4.6% YoY. Net profit margins during the quarter declined from 12.8% in 2QFY19 to 11.4% in 2QFY20.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 2.9% on a quarter-on-quarter (QoQ) basis. The expenses were up by 3.8% QoQ during the same period.
  • The company's operating profit declined by 0.6% QoQ during the quarter. Consequently, operating profit margins witnessed a decline and stood at 20.1% in 2QFY20 as against 20.8% in 1QFY19.
  • Net profit for the quarter increased by 1.3% QoQ, while net profit margins declined from 11.6% in 1QFY19 to 11.4% in 2QFY20.

To see how AUROBINDO PHARMA has performed over the last eight quarters,please visit here.

WATCH NOW: Full Replay of Our Urgent Broadcast on India's Revival

AUROBINDO PHARMA Share Price Performance

Over the last one year,AUROBINDO PHARMA share price has moved down from Rs 780.2 to Rs 401.7, registering a Loss of Rs 378.5 or around 48.5%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 12,958.4 (up 0.3%). Over the last one year it has moved down from 14,276.6 to 12,958.4, a gain of 1,318 points (down 9.2%).

Overall, the S&P BSE SENSEX is up 15.2% over the year.

Current Valuations

At the current price of Rs 401.7, the price to earnings (P/E) ratio of AUROBINDO PHARMA stands at 9.2 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 1.7 times.

Equitymaster requests your view! Post a comment on "AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6%". Click here!

  

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

Hotel Stocks Will Reward Investors(Fast Profits Daily)

Jun 8, 2021

This is why I'm bullish on the hotel and hospitality sector.

Don't Break These 5 Intraday Trading Rules(Fast Profits Daily)

Jun 1, 2021

To become a better intraday trader, follow these rules religiously.

Is the RBI's 'Bubble Talk' Signalling a Market Crash?(Profit Hunter)

May 31, 2021

Is the Indian central bank correct in warning you about a market crash?

Rs 2 Trillion Stimulus Coming to a Stock Market Near You(Profit Hunter)

Jun 2, 2021

Get ready to profit from a massive stimulus that you've never seen before.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jun 11, 2021 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - TEVA PHARMA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS